从定义亚群到跨越多种适应症的靶向治疗进展
Targeted Therapy Evolution from Defining a Sub-population to Crossing Multi-indications.
作者信息
Chen Daohong
机构信息
Research Institute, Changshan Biochemical Pharmaceutical, North Head of Yinchuan Street, Zhengding New District, Shijiazhuang, Hebei, China, 050800.
出版信息
Adv Pharm Bull. 2024 Dec 30;14(4):737-744. doi: 10.34172/apb.43306. Epub 2024 Sep 15.
Abstract
PURPOSE
It tends not only to shed lights on an emerging classification framework of disease according to the shared molecular pathogenesis across various organs/tissues, but also to inspire more efficient paradigms of pharmaceutic innovation in a broader medical perspective.
METHODS
Literature review and re-thinking.
RESULTS
This article has sorted out an updated profile of the outstanding targeted medications with an extending list of clinical indications in oncology and beyond.
CONCLUSION
Pharmaceutic development can be processed in a less risky and more affordable manner through drug repurpose or tissue agnostic approval.
摘要
目的
它不仅有助于根据跨各种器官/组织的共同分子发病机制揭示一种新兴的疾病分类框架，而且从更广泛的医学角度激发更有效的药物创新模式。
方法
文献综述与反思。
结果
本文梳理了一份杰出靶向药物的最新概况，其临床适应症清单在肿瘤学及其他领域不断扩展。
结论
通过药物重新利用或组织agnostic批准，可以以风险更低、成本更低的方式进行药物开发。 （注：“agnostic”这里可能有误，推测可能是“agnostic approach”之类的表述，翻译为“agnostic方法”不太准确，或许是“组织非特异性批准”等更合适，但按要求保留原文翻译）
相似文献
1
Targeted Therapy Evolution from Defining a Sub-population to Crossing Multi-indications.从定义亚群到跨越多种适应症的靶向治疗进展
Adv Pharm Bull. 2024 Dec 30;14(4):737-744. doi: 10.34172/apb.43306. Epub 2024 Sep 15.
2
FDA Approvals of Oncology Drugs for Tissue-Agnostic Indications.FDA 批准用于组织不可知适应症的肿瘤药物。
Target Oncol. 2023 Sep;18(5):777-792. doi: 10.1007/s11523-023-00982-6. Epub 2023 Jul 21.
3
The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development.ESMO 肿瘤不可知分类器和筛查器（ETAC-S）：一种用于评估基于分子靶向治疗的肿瘤不可知性和指导药物开发的工具。
Ann Oncol. 2024 Nov;35(11):936-953. doi: 10.1016/j.annonc.2024.07.730. Epub 2024 Aug 25.
4
Use of pembrolizumab among older adults with cancer in the United States, before and after FDA approval of its tumor-agnostic indication.在美国，FDA 批准 pembrolizumab 的肿瘤不可知适应证之前和之后，在老年癌症患者中的使用情况。
Pharmacoepidemiol Drug Saf. 2024 Jan;33(1):e5745. doi: 10.1002/pds.5745. Epub 2023 Dec 29.
5
Site-agnostic biomarker-guided oncology drug development.基于无靶点生物标志物的肿瘤药物研发。
Expert Rev Mol Diagn. 2020 Jun;20(6):583-592. doi: 10.1080/14737159.2020.1702521. Epub 2019 Dec 12.
6
The evolving landscape of tissue-agnostic therapies in precision oncology.精准肿瘤学中组织不可知治疗方法的不断发展。
CA Cancer J Clin. 2024 Sep-Oct;74(5):433-452. doi: 10.3322/caac.21844. Epub 2024 May 30.
7
Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There?肿瘤学中对新药的不可知论组织学批准：我们是否已经达到了这一目标？
Clin Cancer Res. 2019 Jun 1;25(11):3210-3219. doi: 10.1158/1078-0432.CCR-18-3694. Epub 2019 Jan 22.
8
Developing Drugs for Tissue-Agnostic Indications: A Paradigm Shift in Leveraging Cancer Biology for Precision Medicine.开发针对组织非依赖性适应症的药物：利用癌症生物学实现精准医学的范式转变。
Clin Pharmacol Ther. 2021 Feb;109(2):334-342. doi: 10.1002/cpt.1946. Epub 2020 Jul 16.
9
Highlights of FDA Oncology Approvals in 2022: Tissue-Agnostic Indications, Dosage Optimization, and Diversity in Drug Development.2022 年 FDA 肿瘤学批准的重点：组织非特异性适应症、剂量优化和药物开发中的多样性。
Cancer Discov. 2022 Dec 2;12(12):2739-2746. doi: 10.1158/2159-8290.CD-22-1185.
10
The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab.肿瘤学中加速批准途径的应用：帕博利珠单抗的案例研究
Drugs. 2024 Dec;84(12):1579-1601. doi: 10.1007/s40265-024-02111-7. Epub 2024 Nov 13.
本文引用的文献
1
Making inroads to precision medicine for the treatment of autoimmune diseases: Harnessing genomic studies to better diagnose and treat complex disorders.在自身免疫性疾病治疗中迈向精准医学：利用基因组研究更好地诊断和治疗复杂疾病。
Camb Prism Precis Med. 2023 May 11;1:e25. doi: 10.1017/pcm.2023.14. eCollection 2023.
2
Being precise with anticoagulation to reduce adverse drug reactions: are we there yet?精准抗凝以减少药物不良反应：我们做到了吗？
Pharmacogenomics J. 2024 Mar 5;24(2):7. doi: 10.1038/s41397-024-00329-y.
3
Forget lung, breast or prostate cancer: why tumour naming needs to change.忘掉肺癌、乳腺癌或前列腺癌吧：肿瘤命名为何需要改变。
Nature. 2024 Feb;626(7997):26-29. doi: 10.1038/d41586-024-00216-3.
4
The GLP-1 journey: from discovery science to therapeutic impact.胰高血糖素样肽-1的历程：从发现科学到治疗作用
J Clin Invest. 2024 Jan 16;134(2):e175634. doi: 10.1172/JCI175634.
5
Untoward immune effects of modern medication.现代药物的不良免疫效应。
J Biomed Res. 2023 Dec 18;38(1):17-23. doi: 10.7555/JBR.37.20230071.
6
Glucagon-like peptide agonists: A prospective review.胰高血糖素样肽激动剂：前瞻性综述。
Endocrinol Diabetes Metab. 2024 Jan;7(1):e462. doi: 10.1002/edm2.462. Epub 2023 Dec 14.
7
Evaluation and comparison of efficacy and safety of tirzepatide and semaglutide in patients with type 2 diabetes mellitus: A Bayesian network meta-analysis.评价和比较替西帕肽和司美格鲁肽在 2 型糖尿病患者中的疗效和安全性：一项贝叶斯网络荟萃分析。
Pharmacol Res. 2024 Jan;199:107031. doi: 10.1016/j.phrs.2023.107031. Epub 2023 Dec 5.
8
Low molecular weight heparin decreases mortality and major complication rates in moderately severe and severe acute pancreatitis-a systematic review and meta-analysis.低分子量肝素可降低中度重症和重症急性胰腺炎的死亡率及主要并发症发生率——一项系统评价和荟萃分析
Front Med (Lausanne). 2023 Oct 25;10:1241301. doi: 10.3389/fmed.2023.1241301. eCollection 2023.
9
The History and Development of HER2 Inhibitors.HER2抑制剂的历史与发展
Pharmaceuticals (Basel). 2023 Oct 12;16(10):1450. doi: 10.3390/ph16101450.
10
The role of inflammation in autoimmune disease: a therapeutic target.炎症在自身免疫性疾病中的作用：一个治疗靶点。
Front Immunol. 2023 Oct 4;14:1267091. doi: 10.3389/fimmu.2023.1267091. eCollection 2023.
Zotero 插件